April 11, 2019 09:14 AM EDTUpdated May 30, 12:14 PM
Pharma

Brae­burn pe­ti­tions FDA to re­voke Sublo­cade or­phan des­ig­na­tion

Michael Mezher

A cit­i­zen pe­ti­tion filed last week by law firm Good­win Proc­ter on be­half of Penn­syl­va­nia-based drug­mak­er Brae­burn calls on the FDA to re­voke the or­phan …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times